TRANSCENTA-B (06628): Clover Pharmaceuticals announced updated efficacy data for the first-line treatment of stomach or gastroesophageal junction adenocarcinoma with osemitamab triplet therapy in the I/II phase (Transtar102) at ESMO Asia.

TRANSCENTA-B(06628) announced that the company's board of directors is pleased to announce the updated efficacy analysis of the phase I/II clinical trial (Transtar102) of osemitamab in combination with namunolimab and CAPOX as first-line treatment for gastric or gastroesophageal junction adenocarcinoma based on CLDN18.2 and PD-L1 expression. These study results were presented in a poster format (abstract number: #299P) at the European Society for Medical Oncology Asia Congress 2025 held in Singapore. The new analysis further confirms the encouraging clinical benefits demonstrated by the osemitamab triple therapy. After a median follow-up of 25.8 months, in 26 patients with CLDN18.2 expression 40%, 2+, and known PD-L1 CPS, the median progression-free survival (mPFS) reached 16.6 months, with an objective response rate (ORR) of 68% and a median duration of response (mDoR) of 18 months. It is worth noting that in both subgroups of PD-L1 CPS <1 and 1, patients with higher CLDN18.2 expression had better PFS than those with lower expression, indicating that the potential therapeutic benefits of osemitamab are not influenced by PD-L1 expression levels and are consistent. The safety profile was consistent with the data previously presented at the ASCO 2025 conference. "Exploratory efficacy analysis continues to demonstrate the positive clinical benefits of osemitamab in combination with standard treatment," said Professor Lin Shen, Director of the Department of Digestive Oncology and Phase I Clinical Trial Department at Peking University Cancer Hospital. "The consistent benefits seen in patients in different PD-L1 subgroups are particularly noteworthy, suggesting that this treatment regimen is likely to bring clinically meaningful benefits to a large number of advanced gastric or gastroesophageal junction adenocarcinoma patients." "We are pleased to see the strong clinical benefit signal continuing to be demonstrated in this study, further confirming the potential of osemitamab to provide substantial benefits to patients in need of more effective treatment options," said Dr. Qiu Chuan, Executive Vice President of Clinical Development at Chuangsheng Medicine. "Furthermore, the updated data continues to confirm the good safety and tolerability of osemitamab in combination with namunolimab and CAPOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma."